Literature DB >> 7547864

Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor.

D Jellinek1, L S Green, C Bell, C K Lynott, N Gill, C Vargeese, G Kirschenheuter, D P McGee, P Abesinghe, W A Pieken.   

Abstract

Screening of random oligonucleotide libraries with SELEX [systematic evolution of ligands by exponential enrichment; Tuerk, C., & Gold, L. (1990) Science 249, 505-510] has emerged as a powerful method for identifying high-affinity nucleic acid ligands for a wide range of molecular targets. Nuclease sensitivity of unmodified RNA and DNA, however, imposes considerable restrictions on their use as therapeutics or diagnostics. Modified RNA in which pyrimidine 2'-hydroxy groups have been substituted with 2'-amino groups (2'-aminopyrimidine RNA) is known to be substantially more resistant to serum nucleases. We report here on the use of SELEX to identify high-affinity 2'-aminopyrimidine RNA ligands to a potent angiogenic factor, basic fibroblast growth factor (bFGF). High-affinity ligands with the same consensus primary structure have been isolated from two independent libraries of approximately 6 x 10(14) molecules containing 30 or 50 randomized positions. Compared to unmodified RNA with the same sequence, 2'-aminopyrimidine ligands are at least 1000-fold more stable in 90% human serum. The sequence information required for high-affinity binding to bFGF is contained within 24-26 nucleotides. The minimal ligand m21A (5'-GGUGUGUGGAAGACAGCGGGUGGUUC-3'; G = guanosine, A = adenosine, C = 2'-amino-2'-deoxycytidine, U = 2'-amino-2'-deoxyuridine, and C = 2'-amino-2'-deoxycytidine or deoxycytidine) binds to bFGF with an apparent dissociation constant (Kd) of 3.5 +/- 0.3) x 10(-10) M at 37 degrees C in phosphate-buffered saline (pH 7.4). Disassociation of m21A from bFGF is adequately described with a first-order rate constant of (1.96 +/- 0.08) x 10(-3) s-1 (t1/2 = 5.9 min). The calculated value for the association rate constant (kon = k(off)/Kd) was 5.6 x 10(6) M-1 s-1. Highly specific binding of m21A to bFGF was observed: binding to denatured bFGF, five proteins from the FGF family (acidic FGF, FGF-4, FGF-5, FGF-6, and FGF-7), and four other heparin binding proteins is substantially weaker under the same conditions with KdbFGF/Kdprotein values ranging from (4.1 +/- 1.4) x 10(-2) to > 10(-6). Heparin but not chondroitin sulfate competed for binding of m21A to bFGF. In cell culture, m21A inhibited [125I]bFGF binding to both low-affinity sites (ED50 approximately 1 nM) and high-affinity sites (ED50 approximately 3 nM) on CHO cells expressing transfected FGF receptor-1.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547864     DOI: 10.1021/bi00036a009

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  59 in total

1.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing.

Authors:  Xianbin Yang; Suzanne E Bassett; Xin Li; Bruce A Luxon; Norbert K Herzog; Robert E Shope; Judy Aronson; Tarl W Prow; James F Leary; Romy Kirby; Andrew D Ellington; David G Gorenstein
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

3.  Development of DNA aptamers using Cell-SELEX.

Authors:  Kwame Sefah; Dihua Shangguan; Xiangling Xiong; Meghan B O'Donoghue; Weihong Tan
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

Review 4.  Nucleic acid aptamers: clinical applications and promising new horizons.

Authors:  X Ni; M Castanares; A Mukherjee; S E Lupold
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Authors:  William M Rockey; Frank J Hernandez; Sheng-You Huang; Song Cao; Craig A Howell; Gregory S Thomas; Xiu Ying Liu; Natalia Lapteva; David M Spencer; James O McNamara; Xiaoqin Zou; Shi-Jie Chen; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-10       Impact factor: 5.486

Review 6.  Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates.

Authors:  Jung Heon Lee; Mehmet V Yigit; Debapriya Mazumdar; Yi Lu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-22       Impact factor: 15.470

Review 7.  Colorimetric biosensors based on DNAzyme-assembled gold nanoparticles.

Authors:  Juewen Liu; Yi Lu
Journal:  J Fluoresc       Date:  2004-07       Impact factor: 2.217

8.  Calcium-dependent oligonucleotide antagonists specific for L-selectin.

Authors:  D O'Connell; A Koenig; S Jennings; B Hicke; H L Han; T Fitzwater; Y F Chang; N Varki; D Parma; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

9.  RNA mimetics: oligoribonucleotide N3'-->P5' phosphoramidates.

Authors:  S M Gryaznov; H Winter
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

10.  Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers.

Authors:  Xianbin Yang; Xin Li; Tarl W Prow; Lisa M Reece; Suzanne E Bassett; Bruce A Luxon; Norbert K Herzog; Judy Aronson; Robert E Shope; James F Leary; David G Gorenstein
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.